Buvidal is a new medication that has been funded by the Welsh Government and is a new form of opiate substitution treatment. There have been several academic research studies published on the back of its success, but this is the first peer-led evaluation of the medication.

A group of peers – some on Buvidal themselves, completed extensive interviews with service users and recorded both the negative and positive aspects of this new medication.

As with the CV19 impact study, the peer costs for this study were funded by the Welsh Government in their commitment to service user review.

For more information click here